Vaccine development companies FluGen and Bharat Biotech have partnered with the University of Wisconsin–Madison (UWMadison) to develop and evaluate a Covid-19 vaccine candidate, CoroFlu.
CoroFlu will be based on FluGen’s flu vaccine candidate M2SR, said to be a self-limiting formulation of the influenza virus that triggers an immune response against the infection.
Researchers at UWMadison will incorporate SARS-CoV-2 gene sequences into M2SR to create a vaccine that could generate immunity against the novel coronavirus.
Similar to M2SR, CoroFlu will be administered intranasally with an aim to induce multiple immune responses. FluGen co-founder Gabriele Neumann said: “We are going to modify M2SR by adding part of the coding region for